Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives $36.67 Average Target Price from Brokerages

Shares of Bicara Therapeutics Inc. (NASDAQ:BCAX) have received a consensus rating of “Buy” from the eight research firms that are currently covering the stock, MarketBeat Ratings reports. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $36.50.

A number of brokerages recently commented on BCAX. HC Wainwright reduced their price objective on shares of Bicara Therapeutics from $45.00 to $44.00 and set a “buy” rating for the company in a research note on Monday. Cantor Fitzgerald restated an “overweight” rating and set a $13.01 price objective on shares of Bicara Therapeutics in a research note on Thursday, March 13th. Wedbush reaffirmed an “outperform” rating and set a $31.00 price objective on shares of Bicara Therapeutics in a research report on Thursday, March 27th. Finally, Stifel Nicolaus set a $48.00 target price on shares of Bicara Therapeutics in a report on Thursday, March 27th.

Bicara Therapeutics Stock Performance

BCAX stock opened at $9.51 on Friday. Bicara Therapeutics has a 1-year low of $9.02 and a 1-year high of $28.09. The business has a 50-day moving average price of $13.03 and a 200 day moving average price of $17.36.

Bicara Therapeutics (NASDAQ:BCAX) last posted its quarterly earnings results on Thursday, March 27th. The company reported ($0.39) EPS for the quarter, missing the consensus estimate of ($0.31) by ($0.08). On average, equities analysts anticipate that Bicara Therapeutics will post -2.59 EPS for the current year.

Institutional Investors Weigh In On Bicara Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in BCAX. Geode Capital Management LLC purchased a new stake in shares of Bicara Therapeutics during the third quarter worth about $1,239,000. FMR LLC acquired a new position in Bicara Therapeutics during the 3rd quarter valued at approximately $57,913,000. Wellington Management Group LLP purchased a new position in shares of Bicara Therapeutics in the third quarter worth $19,458,000. Point72 Asset Management L.P. purchased a new position in shares of Bicara Therapeutics in the third quarter worth $9,474,000. Finally, Janus Henderson Group PLC acquired a new stake in shares of Bicara Therapeutics during the third quarter worth $30,329,000.

About Bicara Therapeutics

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.